Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marijo Bilusic

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
The Oncologist|January 14, 2023
A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid TumorsMargaret E Gatti-Mays, Nicholas P Tschernia, Julius Strauss, et al.
Journal for Immunotherapy of Cancer|September 4, 2021
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancerPeter J DeMaria, Katherine Lee-Wisdom, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancerHoussein Abdul Sater, Jennifer L Marté, Renee N Donahue, et al.
The Oncologist|May 3, 2023
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate CancerRavi A Madan, Marijo Bilusic, Mark N Stein, et al.
Journal for Immunotherapy of Cancer|March 5, 2021
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancerRavi A Madan, Fatima Karzai, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer|December 16, 2020
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignanciesJulius Strauss, Margaret E Gatti-Mays, Byoung Chul Cho, et al.
European Urology Oncology|November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 TrialFern Anari, John O'Neill, Woonyoung Choi, et al.
Journal for Immunotherapy of Cancer|December 6, 2018
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, David VanderWeele, Ravi A Madan, et al.
European Urology|August 5, 2015
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerElizabeth R Plimack, Roland L Dunbrack, Timothy A Brennan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic ResponseFatima Karzai, Stephanie M Walker, Scott Wilkinson, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
The Oncologist|January 14, 2023
A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid TumorsMargaret E Gatti-Mays, Nicholas P Tschernia, Julius Strauss, et al.
Journal for Immunotherapy of Cancer|September 4, 2021
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancerPeter J DeMaria, Katherine Lee-Wisdom, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancerHoussein Abdul Sater, Jennifer L Marté, Renee N Donahue, et al.
The Oncologist|May 3, 2023
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate CancerRavi A Madan, Marijo Bilusic, Mark N Stein, et al.
Journal for Immunotherapy of Cancer|March 5, 2021
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancerRavi A Madan, Fatima Karzai, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer|December 16, 2020
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignanciesJulius Strauss, Margaret E Gatti-Mays, Byoung Chul Cho, et al.
European Urology Oncology|November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 TrialFern Anari, John O'Neill, Woonyoung Choi, et al.
Journal for Immunotherapy of Cancer|December 6, 2018
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, David VanderWeele, Ravi A Madan, et al.
European Urology|August 5, 2015
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerElizabeth R Plimack, Roland L Dunbrack, Timothy A Brennan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic ResponseFatima Karzai, Stephanie M Walker, Scott Wilkinson, et al.
Pageof 8